Ketamine in Severe Traumatic Brain Injury
Neurophysiological Effect of Ketamine in Patients With Severe Traumatic Brain Injury
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- Parkland Memorial Hospital
-
Contact:
- Anna Bashmakov, D.O.
- Phone Number: 214-648-4827
- Email: Anna.Bashmakov@UTSouthwestern.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Severe traumatic brain injury
- Placement of intracranial monitor for measurement of intracranial pressure and brain tissue oxygenation
- Age greater than or equal to 18 years
Exclusion Criteria:
- Documented allergy to ketamine
- Sinus tachycardia with sustained heart rate >120
- Any episode of non-sinus tachycardia
- Documented history of schizophrenia
- Systolic blood pressure > 180, diastolic blood pressure > 120
- Documented episode(s) of ICP elevations >25 mm Hg sustained greater than 5 minutes within 24 hours
- Similar episodes as above of PbtO2 <15 mmHg
- Positive pregnancy test and/or is currently breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Ketamine Intervention Arm
A single dose of 0.5 mg/kg (actual body weight) of ketamine will be administered intravenously.
Ketamine will be administered in addition to the patient's existing analgesia, sedation and other medicines as a part of their routine treatment.
|
Administration of ketamine with subsequent measurement of intracranial pressure and brain tissue oxygenation
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intracranial Pressure (ICP, measured by external ventricular drain and/or ICP monitor)
Time Frame: 3 hours
|
Measurement of pressure within the rigid skill, with values greater than 22 mm Hg sustained proven to be injurious in patients with traumatic brain injury
|
3 hours
|
|
Brain tissue oxygenation (measured by intracranial oxygen probe)
Time Frame: 3 hours
|
Measurement of the concentration of oxygen within the brain tissue, with values less than 20 mmHg sustained proven to be injurious in patients with traumatic brain injury
|
3 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Anna Bashmakov, D.O., University of Texas Southwestern Medical Center
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STU-2023-0805
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.